SublingualAllergic rhinitis caused by house dust miteAdult: Dermatophagoides farinae 6 SQ-house dust mite (HDM) and Dermatophagoides pteronyssinus 6 SQ-HDM tab
1 tab daily. Administer the initial dose under medical supervision and monitor patient for 30 minutes for any adverse reactions. If tolerated, subsequent doses may be taken without physician supervision. Refer to detailed treatment guidelines for the recommended duration of treatment.
SublingualAllergic asthma due to house dust miteAdult: Dermatophagoides farinae 6 SQ-house dust mite (HDM) and Dermatophagoides pteronyssinus 6 SQ-HDM tab
In cases not well controlled by inhaled corticosteroids and associated with allergic rhinitis caused by house dust mite: 1 tab daily. Administer the initial dose under medical supervision and monitor patient for 30 minutes for any adverse reactions. If tolerated, subsequent doses may be taken without physician supervision. Refer to detailed treatment guidelines for the recommended duration of treatment.
|
Hypersensitivity to D. farinae or D. pteronyssinus. Severe, uncontrolled, unstable asthma; history of severe asthma exacerbation within the last 3 months; history of severe systemic allergic reaction; history of severe local reaction associated with any sublingual allergen immunotherapy; acute respiratory tract infection; history of eosinophilic oesophagitis; severe oral inflammations or oral wounds; active or poorly controlled autoimmune diseases, immune defects, immunodeficiencies, immunosuppression or malignant neoplastic Patient with FEV1 <70% of predicted value (after adequate treatment) at treatment initiation. Pregnancy (prior to treatment).
|
Patient with certain medical conditions that may decrease survival to serious allergic reactions (e.g. markedly compromised lung function [acute or chronic], severe mast cell disorder, CV conditions including unstable angina, recent MI, significant arrhythmia, uncontrolled hypertension). Not intended for immediate relief of allergic symptoms or treatment of acute asthma exacerbations. Pregnancy (which occurred during treatment) and lactation.
|
Significant: Acute asthma exacerbation, eosinophilic oesophagitis.
Cardiac disorders: Chest pain.
Ear and labyrinth disorders: Ear pruritus.
Eye disorders: Eye pruritus.
Gastrointestinal disorders: Mouth oedema, lip oedema, glossitis, mouth ulceration, stomatitis, oral pruritus, lip pruritus, tongue pruritus, oropharyngeal pain or discomfort, paraesthesia oral, nausea, abdominal pain, diarrhoea, dyspepsia, dysphagia, dysgeusia.
Respiratory, thoracic and mediastinal disorders: Throat irritation, cough, pharyngeal oedema, dyspnoea, bronchitis, nasopharyngitis, pharyngitis, rhinitis, sinusitis.
Skin and subcutaneous tissue disorders: Pruritus, urticaria.
Potentially Fatal: Hypersensitivity reaction (e.g. anaphylaxis, severe laryngopharyngeal restriction).
|
Perform house dust mite sensitisation (specific IgE and/or skin prick) test prior to treatment. Monitor for signs and symptoms of hypersensitivity. Assess asthma status prior to treatment.
|
Symptoms: Hypersensitivity reactions (e.g. systemic allergic reactions, severe local allergic reactions); severe adverse reactions (e.g. angioedema, difficulty in swallowing, difficulty in breathing, changes in voice, feeling of fullness in the throat). Management: Symptomatic treatment. Administer epinephrine if necessary.
|
Description:
Mechanism of Action: Dermatophagoides farinae and Dermatophagoides pteronyssinus are house dust mite species. Allergen extracts from these species are utilized for allergen immunotherapy. Its exact mechanism of action has not been fully determined but it may be involved in modifying the immune response to HDM allergens by increasing HDM-specific IgG4 antibodies, thus inducing a systemic response that can compete with IgE antibodies for allergen binding.
|
Store between 20-25°C. Protect from light and moisture.
|
|
|
Acarizax (Abbott). MIMS Philippines. http://www.mims.com/philippines. Accessed 10/08/2023. Acarizax 12 SQ-HDM Oral Lyophilisate (ALK-Abello A/S). MHRA. https://products.mhra.gov.uk. Accessed 10/08/2023. Acarizax 12 SQ-HDM Oral Lyophilisate Tablet (Abbott Laboratories [M] Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 10/08/2023. Actair 300 IR Sublingual Tablets (Stallergenes). MHRA. https://products.mhra.gov.uk. Accessed 10/08/2023. Anon. House Dust Mite Allergen Extract. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 10/08/2023. Joint Formulary Committee. House Dust Mite Extract. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/08/2023. Odactra Tablet (ALK-Abello A S). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 10/08/2023. Sequiris NZ Ltd. Acarizax 12 SQ-HDM Sublingual Tablet data sheet 21 February 2022. Medsafe. http://www.medsafe.govt.nz. Accessed 10/08/2023.
|
Sign Out
